PMC9502244_01
CT scanning revealed that bilateral adrenal hyperplasia before the treatment. (a) Unenhanced CT scanning and (b) contrast material-enhanced CT scanning.
10.1177_17455057221122597-fig1.jpg
PMC9502244_01_10.1177_17455057221122597-fig1.jpg
fig1-17455057221122597
Computed tomography (CT) scanning (unenhanced and contrast material-enhanced scanning) suggested the hyperplasia in bilateral adrenal gland (Figure 1).
The CYP17A1 genetic mutation sequence of the patient and her parents. (a) Normal reference sequence of CYP17A1 gene. (b) The CYP17A1 genetic sequence of the patient showed GACTCTTTC bases deletion at nucleotide position 1459-1467 in exon 8. (c) The CYP17A1 genetic sequence of the patient's father showed GACTCTTTC heterozygous mutation. (d) The CYP17A1 genetic sequence of the patient's mother showed GACTCTTTC heterozygous mutation.
10.1177_17455057221122597-fig2.jpg
PMC9502244_01_10.1177_17455057221122597-fig2.jpg
fig2-17455057221122597
The patient's father and mother were all heterozygous carriers of this mutation (Figure 2).
The re-examined adrenal unenhanced CT scanning of the patient showed that the adrenal hyperplasia did not aggravated over 3 years after treatment.
10.1177_17455057221122597-fig3.jpg
PMC9502244_01_10.1177_17455057221122597-fig3.jpg
fig3-17455057221122597
And the re-examined adrenal unenhanced CT scanning of the patient showed that the adrenal hyperplasia did not aggravated (Figure 3).